24 October 2023: Aker BioMarine ASA today announces that it has acquired all
krill related patents, pre-clinical and clinical data, and processing equipment
from Nasdaq listed Acasti Pharma Inc. The transaction is a settlement towards a
contractual obligation of USD 3.1 million Acasti has towards Aker BioMarine, and
has no cash effects.

With this transaction Aker BioMarine continues to consolidate all relevant krill
intellectual properties (IP), and further strengthen its leadership position. 

The data acquired, which documents the strong cardiovascular benefits from krill
oil, will further strengthen the attractiveness of Superba® krill oil in the
dietary supplement market. In addition, this gives Aker BioMarine an option to
later pursue pharmaceutical opportunities originated from Acasti Pharma Inc. The
company currently has no plans of pursuing that option.  
   

For further information, please contact 
Christopher Robin Vinter, VP IR & Corporate Finance
Mobile: +47 911 60 820 
Email:  Christopher.vinter@akerbiomarine.com  

About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for consumer health and wellness as
well as animal nutrition. The company has a strong position in its industry and
is the world's leading supplier of krill, the natural, powerful and health
promoting source of nutrients from the pristine waters of Antarctica. Aker
BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available
at www.akerbiomarine.com.